Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Licensure Observational Study of the Safety of GARDASIL™ in Males

NCT01567813 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT01567813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01567813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Licensure Observational Study of the Safety of GARDASIL™ in Males
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Observational
Overall status
Completed
Start date
June 23, 2011
Completion date
June 1, 2019
Enrollment
114,035 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human papilloma virus infection